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Introduction: Sulfonylurea antidiabetics are insulin secretogogues useful in the treatment of 
type 2 diabetic patients. The probability of adverse drug interactions is high in patients taking 
sulfonylureas and other drugs including herbal medicines. The present review is aimed to 
present  the herbal drugs having interacting potentials with sulfonylurea antidiabetics. 
Methods: The databases such as PubMed, Google Scholar, Science Direct, Directory of open 
access journals (DOAJ) and reference lists were searched using the keywords drug interactions, 
Sulfonylureas, pharmacodynamic interactions, antidiabetic herbs, pharmacokinetic 
interactions and CYP2C9. 
Results: Sulfonylureas are primarily metabolized by CYP2C9 enzyme and the herbs like St. 
John’s wort and Ginkgo biloba induce CYP2C9-mediated metabolism of sulfonylureas while 
fruit juices like Pomegranate juice and Pineapple juice inhibit their metabolism. In addition, 
the antidiabetic herbal supplements such as Bitter melon, Fenugreek, Cinnamon, Gymnema, 
Ginseng, Ginger, Garlic, Aloe vera, Sesame, Andrographis paniculata and Neem potentiate the 
hypoglycemic activity of sulfonylureas, pharmacodynamically. 
Conclusion: Some herbal supplements are capable of interacting pharmacokinetically and 
pharmacodynamically with sulfonylurea antidiabetics
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A B S T R A C T
Introduction
Diabetes mellitus (DM) is a chronic metabolic condition 
in which hyperglycemia is noted for a longer duration (1). 
It is a global health burden and the incidence of diabetes 
among global population is increasing every year. It has 
been estimated that 171 million of world population were 
affected by diabetes in the year of 2000 (2), 285 million 
in 2010 (3), 366 million in 2011 (4), 382 million in 2013 
(5), 415 million in 2015 (6) and 451 million in 2017 (7). 
The prevalence of diabetes around the globe has been 
projected as 552 million by 2030 (8), 592 million by 2035 
(9), 642 million by 2040 (10) and 693 million by 2045 (11).
DM is sorted mainly as type 1 DM which is insulin-
dependent (IDDM) and type 2 DM, the non-insulin 
dependent (NIDDM). DM could be managed by both 
non-pharmacological and pharmacological therapies. 
Non-pharmacological management of diabetes includes 
lifestyle modifications such as dietary interventions, 
increased physical activity and smoking cessation. 
(12). Type 1 diabetes is managed pharmacologically 
by administering insulin injections mainly and the 
pharmacological management of type 2 diabetes includes 
the use of antidiabetic medications such as metformin, 
sulfonylureas, meglitinides (repaglinide and nateglinide), 
thiazolidinediones (rosiglitazone and pioglitazone), alpha 
glucosidase inhibitors (acarbose and miglitol), dipeptidyl 
peptidase 4 (DPP4) inhibitors (sitagliptin, saxagliptin, 
linagliptin, etc), SGLT2 inhibitors (dapagliflozin, 
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canagliflozin, etc.), GLP-1 agonists (exenatide, liraglutide, 
etc) and amylin analogue (pramlintide) (13).
Sulfonylurea antidiabetics reduce the blood sugar levels 
by inducing the release of insulin from beta cells of 
pancreas (14). They include first-generation drugs such as 
Tolbutamide, Chlorpropamide, etc and second-generation 
drugs like gliclazide, glipizide, glibenclamide, etc (15).
Nowadays, the use of complementary and alternative 
medicine (CAM) is common amongst patients with 
diabetes and other common chronic problems. It has 
been estimated that 9.8%–76.0% of general population 
tend to use CAM, globally (16). The CAM use found high 
in people such as women, those with literacy, those with 
employment, those with poor physical health, and those 
with diabetes or its comorbidities (17). Furthermore, 
it has been reported that the prevalence of CAM use in 
patients with diabetes is approximately 48% (18). The 
most frequently used CAM treatments among patients 
with diabetes include herbal medicines, nutritional advice, 
spiritual healing, massage, and meditation (19). 
Herbal supplement use is getting popular among general 
population. A study from the United States found that 
approximately 35% of 26 157 participants used at least 
one herbal supplement (20). Up to 80% of population in 
developing countries use traditional herbal medicines as 
World Health Organization estimated it (21).
A study from Saudi Arabia comprising 228 patients with 
diabetes revealed that 24.6% of participants used herbal 
supplements (22) and an Iraqi study conducted among 
884 diabetic patients found that 17.3% (153 respondents) 
of them used herbal supplements (23).
Drug interaction is defined as the interference of effects 
of one drug by the co-administered drugs, herbs, alcohol 
or tobacco smoke (24). The drug interaction leading to 
undesirable effects such as increased adverse effects 
or decreased beneficial effects, is termed ‘adverse drug 
interaction’. The patients with diabetes are at heightened 
risk of adverse drug interactions, as they concomitantly 
use many medications to manage their comorbidities such 
as hypertension, dyslipidemia, heart diseases, depression, 
infections, etc, along with their antidiabetic medications 
(25). The probability of adverse drug interactions in 
diabetic patients is particularly high in patients who use 
sulfonylureas with herbal medicines. The present review 
is aimed to present the herbal drugs having interacting 
potentials with sulfonylurea antidiabetics.
Methods 
The literature was searched in databases such as PubMed, 
Google Scholar, Science Direct, Directory of open access 
journals (DOAJ) and reference lists were searched 
using the keywords Drug interactions, Sulfonylureas, 
Pharmacodynamic interactions, Antidiabetic herbs, 
Pharmacokinetic interactions and CYP2C9. 
Results
The herbal supplements taken by diabetic patients may 
interact with sulfonylureas either pharmacokinetically 
or pharmacodynamically. Sulfonylurea antidiabetics 
are metabolised primarily by cytochrome P450 2C9 
(CYP2C9) enzyme (26) and by CYP3A4 enzyme to 
a lesser extent (27). Hence, the herbal drugs capable 
of modulating CYP enzymes may interact with 
sulfonylureas, pharmacokinetically (Table 1). As it was 
stated sulfonylureas are potent antidiabetic drugs and their 
concomitant use with certain herbs having antidiabetic 
activity may enhance the risk of hypoglycemia (Table 2). 
St John’s Wort (Hypericum perforatum)
St John’s Wort is a herbal drug popularly used to treat 
depression. It can induce many CYP enzymes including 
CYP3A4 and CYP2C9 (28). The plasma concentrations of 
gliclazide decreased due to the concomitant use of St John’s 
Wort, which could induce the CYP-mediated metabolism 
of gliclazide. It is recommended to monitor the signs of 
reduced hypoglycemic activity of sulfonylureas in patients 
with diabetes taking the combination of sulfonylureas and 
St John’s Wort (29).
Ginkgo biloba
Ginkgo biloba may be useful to treat some neurological, 
psychological, and behavioral disorders. 
The animal (30) and clinical (31) studies have identified 
that CYP2C9-mediated metabolism of tolbutamide 
Table 1. Pharmacokinetic Herb – Sulfonylureas Interactions
Interacting Drugs Mechanism of Interaction Comments
St John's Wort (Hypericum 
perforatum)
St John's Wort may induce CYP-mediated 
metabolism of sulfonylureas and 
decrease their plasma concentrations.
Monitor the signs of reduced hypoglycemic activity of 
sulfonylureas in patients with diabetes taking the combination 
of sulfonylureas and St John's Wort (29).
Ginkgo biloba Ginkgo biloba may decrease the plasma 
concentrations of sulfonylureas (31). 
The hypoglycemic effect of sulfonylureas may be decreased.
Pomegranate (Punica granatum) 
Juice
Pomegranate Juice may inhibit CYP2C9-
mediated metabolism of sulfonylureas.
Pomegranate Juice potentiate the hypoglycemic effect of 
tolbutamide (32).
Pineapple juice
The pineapple juice may inhibit the 
CYP2C9-mediated metabolism of 
sulfonylureas.
The plasma concentrations of sulfonylureas might be elevated 
by pineapple juice.
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Table 2. Pharmacodynamic herb – sulfonylureas interactions
Interacting Drugs Mechanism of Interaction Comments
Bitter melon 
(Karela) (Momordica 
charantia)
Bitter melon may reduce blood sugar by exhibiting sulfonylurea like 
activity (35), improving glucose tolerance (36, 37), decreasing insulin 
resistance (38), increasing tissue glucose uptake (39, 40) or by increasing 
insulin sensitivity (41).  
Additive reductions in blood glucose may 
result if sulfonylureas are used in patients 
consuming bitter melon regularly (43).
Fenugreek 
(Trigonella foenum-
graceum)
Fenugreek may exert its hypoglycemic activity through improved insulin 
resistance in adipocytes (47) and liver (48), enhanced glucose uptake 
(49), increased activities of hepatic enzymes such as glucokinase and 
hexokinase (50), elevation of serum insulin levels (51) and increased 
insulin sensitivity (52). 
Fenugreek use in patients taking 
sulfonylureas may further decrease the 
blood glucose levels (53, 54).
Cinnamon
Antihyperglycemic effect of Cinnamon may occur through insulin mimetic 
activity (59, 60), reduction of insulin resistance (61, 62), inhibition of 
pancreatic α-amylase and α-glucosidase enzymes (63), enhancement of 
glucose uptake (64), stimulation of glycogen synthesis (65), inhibition of 
gluconeogenesis (66) and delayed gastric emptying (67). 
The dose of sulfonylureas may need to be 
adjusted if the patient is taking cinnamon 
concurrently (68).
Gymnema 
(Gymnema sylvestre)
Gymnema may reduce the glucose levels by delaying glucose absorption 
(74), enhancing insulin secretion (75-77), increasing glucose uptake in 
the liver, kidney and muscle (78) and inducing repair or regeneration of 
pancreatic beta cells (79, 80).  
Concomitant use of sulfonylureas and 
Gymnema may result in potentiation of 
hypoglycemic effects (81, 82). 
Ginseng
Ginseng may produce its antihyperglycemic activity by stimulating insulin 
production and preventing β cell loss (87-89), stimulating insulin release 
(90-93), improving insulin sensitivity (94-96), decreasing insulin resistance 
(97, 98), increasing glucose uptake (99-101), suppressing hepatic glucose 
production (102, 103), improving the regulation of plasma glucose 
and plasma insulin (104) and improving the expression of Peroxisome 
proliferator-activated receptors (PPARγ) (105, 106).  
Ginseng may potentiate the hypoglycemic 
activity of sulfonylureas (107).
Ginger (Zingiber 
officinale)
Ginger may exhibit its antihyperglycemic activity through improvement 
of insulin resistance (111, 112), enhancement of glucose uptake (113, 
114), increased insulin synthesis (115), decreased gluconeogenesis 
and glycogenolysis and increased glycogenesis (116) and inhibition of  
α-glucosidase and α-amylase enzymes (117). 
The blood glucose levels should be 
monitored in patients taking sulfonylureas 
and ginger together, to avoid the 
occurrence of hypoglycemia (118).
Garlic (Allium 
Sativum)
Garlic may decrease the blood glucose levels through direct or indirect 
stimulation of insulin secretion (123,124), enhanced glucose utilization 
(125) and slowing down glucose absorption (126). 
Caution should be applied in patients 
taking sulfonylureas and garlic together 
(127,128). 
Aloe vera (Aloe 
barbadensis Miller)
Aloe vera may exert it’s hypoglycemic activity by improving insulin 
resistance (135-137), stimulating the release of insulin (138), inhibiting 
pancreatic α-amylase activity (139), increasing glucose utilization and 
suppressing glucose production (140).  
Aloe vera can potentiate the hypoglycemic 
effect of sulfonylureas (141). 
Sesame oil 
[Sesamum indicum]
Diabetes patients may prefer sesame oil as it reduces the detrimental 
effects of diabetes by improving glucose control, blood pressure, lipid 
levels and cardiac and renal health (149-152). 
Sesame oil may improve hyperglycemia of 
patients taking sulfonylureas (153). 
Andrographis 
paniculata
Androdrographolide of Andrographis paniculata reduced the plasma 
glucose in streptozotocin-induced diabetic rats by increasing glucose 
utilization (154). 
Use Andrographis paniculata 
(Androdrographolide) with caution in 
patients taking sulfonylureas to avoid the 
risk of hypoglycemia (155).
Neem (Azadirachta 
indica)
A. indica found to decrease the blood glucose level by improving 
carbohydrate metabolism through the stimulation of the β-cells in 
streptozotocin-induced diabetic mice (157). 
Concomitant use of aqueous extract of 
A. indica with gliclazide produced good 
control of blood glucose (158).
is induced significantly by G. biloba extract, resulting 
in decreased plasma concentrations and reduced 
hypoglycemic effect of tolbutamide.
Pomegranate (Punica granatum) juice
Pomegranate juice may inhibit CYP2C9 activity and 
increase the plasma concentration of tolbutamide resulting 
in potentiation of the hypoglycemic effect (32).
Pineapple juice
Pineapple juice contains bromelain as the principal 
component and it has been shown that CYP2C9 activity 
Journal of Herbmed Pharmacology, Volume 7, Number 3, July 2018http://www.herbmedpharmacol.com 203
Herb-drug interactions of sulfonylureas
is inhibited strongly by Pineapple juice in vitro (33). 
The pineapple juice may inhibit the CYP2C9-mediated 
metabolism of sulfonylureas and elevate their plasma 
concentrations due to its very strong CYP2C9 inhibitory 
activity, in vitro.
In the following section the possible interaction of 
sulfonylureas with medicinal plants which have antidiabetic 
activities are presented.
Bitter melon or bitter gourd (Momordica charantia)
Bitter melon (Karela) is a tropical and subtropical vegetable 
and it is used traditionally to treat diabetes, abdominal 
pain, jaundice, cough, respiratory diseases, skin diseases, 
wounds, ulcer, gout and rheumatism, etc (34). It is 
commonly included in Asian diet. Bitter melon may 
reduce blood sugar by exhibiting sulfonylurea like activity 
(35), improving glucose tolerance (36,37), decreasing 
insulin resistance (38), increasing tissue glucose uptake 
(39,40) or by increasing insulin sensitivity (41). The active 
principles, which may be responsible for the hypoglycemic 
activity of bitter melon, include polypeptide P, momordin, 
charantin and vicine (42). 
Additive reductions in blood glucose may result if 
sulfonylureas are used in patients consuming bitter 
melon regularly. Potentiation of hypoglycemic activity 
of glibenclamide was also noted in patients taking bitter 
melon extract (43). Blood sugar should be monitored and 
the dosage adjustment of sulfonylureas may be necessary 
to avoid hypoglycemic complications.
Fenugreek (Trigonella foenum-graceum)
Fenugreek is a popular condiment and is largely produced 
in Indian subcontinent. Traditional uses of fenugreek 
include antidiabetic, analgesic, anti-inflammatory, anti-
atherosclerotic, carminative, laxative, antispasmodic, 
anticancer, sexual stimulant, astringent, cardio tonic, 
antihypertensive, anti-triglyceridemic, lactation stimulant 
and oxytocic (44). Fenugreek contains constituents like 
carbohydrates, proteins, lipids, alkaloids, flavonoids, 
fibers, saponins, steroidal saponins, vitamins, minerals, 
etc (45). But, the hypoglycemic activity of fenugreek 
majorly determined by the active principles such as 
4-hydroxyleucine, galactomannan rich fiber, and saponins 
(46). Fenugreek may exert its hypoglycemic activity 
through improved insulin resistance in adipocytes (47) 
and liver (48), enhanced glucose uptake (49), increased 
activities of hepatic enzymes such as glucokinase and 
hexokinase (50), elevation of serum insulin levels (51), 
and increased insulin sensitivity (52). Fenugreek use in 
patients taking sulfonylureas may further decrease the 
blood glucose levels (53,54). 
Fenugreek seed extract exhibited synergistic effect on 
hypoglycemic potential of glibenclamide. Caution is 
advised in patients taking an antidiabetic drug and a herb 
like Fenugreek concomitantly, to prevent hypoglycemic 
complications (55).
Cinnamon
Cinnamon is an inner bark of the trees of the genus 
Cinnamomum. Cinnamon is commonly used as a spice 
in many countries. There are many species of cinnamon 
available all around the world, which includes True 
cinnamon or Sri Lanka cinnamon or Ceylon cinnamon 
(Cinnamomum verum or Cinnamomum zeylanicum), 
Chinese cinnamon or cassia cinnamon (Cinnamomum 
cassia), Indonesian cinnamon (Cinnamomum burmannii), 
Vietnamese cinnamon or Saigon cinnamon (Cinnamomum 
loureiroi), etc (56). Many studies have confirmed that 
Cinnamon possesses antidiabetic, cholesterol-lowering, 
antioxidant, antitumor, anti-inflammatory, antimicrobial, 
cardio-vascular and immunomodulatory effects (57). 
Active chemical constituents of cinnamon include 
cinnamaldehyde, coumarins, essential oils, procyanidins, 
etc (58). Antihyperglycemic effect of Cinnamon may 
occur through insulin mimetic activity (59,60), reduction 
of insulin resistance (61,62), inhibition of pancreatic 
α-amylase and α-glucosidase enzymes (63), enhancement 
of glucose uptake (64), stimulation of glycogen synthesis 
(65), inhibition of gluconeogenesis (66) and delayed 
gastric emptying (67). 
Addition of cinnamon, improved the glucose control 
and lipid levels in patients with poorly controlled 
type 2 diabetes taking sulfonylureas (68). To prevent 
hypoglycemia, the dose of sulfonylureas may need to be 
adjusted if the patient is taking cinnamon concurrently.
Gymnema (Gymnema sylvestre)
Gymnema is a herb found vastly in India and Srilanka. 
Traditionally, Gymnema is used to treat diabetes, dyspepsia, 
constipation, jaundice, haemorrhoids, cardiopathy, 
asthma, bronchitis and leukoderma. In addition, it 
has been found to contain antidiabetic, antiobesity, 
hypolipidaemic, antimicrobial, antioxidant, diuretic, 
antihelmentic and anti-inflammatory properties (69-71). 
Active phytoconstituents of Gymnema include triterpene 
saponins (gymnemic acids and gymnemasaponins, 
gymnemasides), flavones, anthraquinones, resins, 
alkaloids, etc (72,73). Gymnemic acids of Gymnema is 
responsible for the antidiabetic activity. Gymnema may 
reduce the glucose levels by delaying glucose absorption 
(74), enhancing insulin secretion (75-77), increasing 
glucose uptake in the liver, kidney and muscle (78) and 
inducing repair or regeneration of pancreatic beta cells 
(79,80). 
Significant reduction of fasting blood glucose and lipid 
levels has been noted in patients with type 2 diabetes 
receiving sulfonylurea treatment along with 400 mg of 
Gymnema daily for 18 to 20 months (55, 79). Concomitant 
use of sulfonylureas and Gymnema may result in 
potentiation of hypoglycemic effects (81,82).
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Ginseng
Ginseng root is a popular herb and there are many 
varieties of ginseng available including Asian ginseng 
or Korean ginseng (Panax ginseng) and American 
ginseng (Panax quinquefolius) (83). Ginseng is used in 
traditional Chinese medicine (TCM) to treat diabetes, 
impotence, anorexia, insomnia, palpitation, shortness 
of breath and hemorrhage (84). The active principles 
found in ginseng include ginsenosides, polysaccharides, 
polyynes, flavonoids, peptides, polyacetylenic alcohols 
and volatile oils (85). The most pharmacologically active 
constituents of ginseng are ginsenosides and they possess 
antioxidant, antiinflammatory, anticarcinogenic and 
immunostimulant properties (86). Ginseng may produce 
its antihyperglycemic activity by stimulating insulin 
production and preventing β cell loss (87-89), stimulating 
insulin release (90-93), improving insulin sensitivity 
(94-96), decreasing insulin resistance (97,98), increasing 
glucose uptake (99-101), suppressing hepatic glucose 
production (102,103), improving the regulation of plasma 
glucose and plasma insulin (104) and improving the 
expression of peroxisome proliferator-activated receptors 
(PPARγ) (105, 106). In sum, ginseng may potentiate the 
hypoglycemic activity of sulfonylureas (107). 
Ginger (Zingiber officinale)
Ginger root is used as a cooking spice in foods. 
Traditionally ginger is used to treat various conditions 
including diabetes, asthma, stroke, constipation, 
rheumatism, nervous diseases, gingivitis, toothache, 
etc (108). Phytochemical studies of ginger revealed 
that it contained terpenes (Zingiberene, β-bisabolene, 
α-farnesene, β-sesquiphellandrene, and α-curcumene), 
phenolic compounds (Gingerol, paradols, and shogaol), 
amino acids, raw fiber, ash, protein, phytosterols, 
vitamins and minerals (109,110). Ginger may exhibit 
its antihyperglycemic activity through improvement 
of insulin resistance (111,112), enhancement of 
glucose uptake (113,114), increased insulin synthesis 
(115), decreased gluconeogenesis and glycogenolysis 
and increased glycogenesis (116) and inhibition of 
α-glucosidase and α-amylase enzymes (117).
Concomitant administration of ginger extract (25 or 50 
mg/kg) and glibenclamide (5 mg/kg) in streptozotocin 
(STZ)-induced diabetic rats, decreased the non-fasting 
blood glucose level significantly. The blood glucose levels 
should be monitored in patients taking sulfonylureas and 
ginger together, to avoid the occurrence of hypoglycemia 
(118).
Garlic (Allium sativum)
Garlic is a natural medicinal plant and is used as a 
flavoring substance in food preparations. Garlic found 
helpful to lower blood sugar, reduce cholesterol levels, 
prevent cardiovascular diseases, enhance the immune 
system and regulate blood pressure. It is effective against 
bacterial, viral, fungal and parasitic infections (119). 
The phytochemicals of garlic include sulfur compounds 
(allicin, alliin and agoene), volatile oils, enzymes (allinase, 
peroxidase and miracynase), carbohydrates (sucrose and 
glucose), minerals (selenium), amino acids (cysteine, 
glutamine, isoleucine and methionine), bioflavonoids 
(quercetin and cyanidin, allistatin I and allistatin II) and 
vitamins (C, E, A, niacin, B1 and B2 and betacarotene 
(120). Sulphur compounds of garlic are linked to the 
hypoglycemic activity (121,122). Garlic may decrease the 
blood glucose levels through direct or indirect stimulation 
of insulin secretion (123,124), enhanced glucose utilization 
(125) and reduction of glucose absorption (126).
Greater hypoglycemic activity was noted in streptozotocin-
induced diabetic rats receiving the combination of garlic 
extract (500 mg/kg) and glibenclamide (0.25 or 0.5 mg/
kg) than either of the drug given alone (127). Caution 
should be applied in patients taking sulfonylureas and 
garlic together (127,128). 
Aloe vera (Aloe barbadensis Miller)
Aloe vera is traditionally used to treat various conditions 
in many countries. Active components of Aloe vera include 
anthraquinones (aloin, barbaloin, isobarbaloin, anthranol, 
etc), hormones (auxins and gibberellins), enzymes 
(cyclooxygenase, oxidase, amylase, catalase, lipase, 
alkaline phosphatase, carboxypeptidase), vitamins (B1, 
B2, B6, choline, folic acid, C, α-tocopherol, β-carotene), 
minerals (calcium, sodium, chlorine, manganese, zinc, 
chromium, etc), sugars (cellulose, glucose, mannose, 
etc), amino acids (lysine, threonine, valine, leucine, 
isoleucine, phenylalanine, methionine) (129-131). Aloe 
vera was found to possess therapeutic properties such 
as antidiabetic, antibacterial, antiviral, antifungal, anti-
inflammatory, anticancer, antioxidant, wound healing 
and immunostimulation activities (132-134). Aloe vera 
may exert its hypoglycemic activity by improving insulin 
resistance (135-137), stimulating the release of insulin 
(138), inhibiting pancreatic α-amylase activity (139), 
increasing glucose utilization and suppressing glucose 
production (140).
Significant improvement in blood glucose level and lipid 
levels was seen in diabetic patients taking Aloe vera juice 
(15 mL two times daily) and glibenclamide (10 mg daily) 
concurrently (141). 
Sesame (Sesamum indicum) oil
Sesame oil is widely used for cooking in South India 
and other parts of the world. Sesame oil is composed 
of lignans (sesamin, sesamolin), minerals, vitamins, 
phytosterols, unsaturated fatty acids (linoleic acid, oleic 
acid, etc) and tocopherols (142-144). Many studies have 
shown that sesame oil has antioxidant, antihypertensive, 
antihyperlipidemic, antihyperglycemic, anticarcinogenic 
and immunoregulatory activities (145-148). Diabetes 
patients may prefer sesame oil as it reduces the detrimental 
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effects of diabetes by improving glucose control, blood 
pressure, lipid levels and cardiac and renal health (149-
152).
The type 2 diabetes patients taking the combination 
of sesame oil (~35 g oil/day used in cooking or salad 
preparation) and glibenclamide (5 mg daily) showed a 
greater anti-hyperglycaemic effect (153).
Andrographis paniculata 
Andrographis paniculata is a medicinal plant used 
traditionally to treat various illnesses like infections, liver 
problems, diabetes, etc. The principal constituent of A. 
paniculata is androdrographolide, which has been shown 
to reduce the plasma glucose in streptozotocin-induced 
diabetic rats by increasing glucose utilization (154). 
The hypoglycemic effect of glyburide enhanced 
considerably by the coadministration with 
androdrographolide. The herbal preparations containing 
A. paniculata (androdrographolide) should be used in 
patients taking sulfonylureas with special attention to 
avoid the risk of hypoglycemia (155).
Neem (Azadirachta indica)
Azadirachta indica is a traditionally used medicinal plant, 
which has anti-inflammatory, immunostimulant and 
hypoglycemic activities (156). A. indica found to decrease 
the blood glucose level by improving carbohydrate 
metabolism through the stimulation of the β-cells in 
streptozotocin-induced diabetic mice (157). Concomitant 
use of aqueous extract of A. indica with gliclazide produced 
good control of blood glucose (158).
Conclusion
Use of herbal medicines to treat diabetes is getting 
popular around the world. The herbs like St. John’s wort 
and Gingko biloba induce CYP2C9-mediated metabolism 
of sulfonylureas while the fruit juices like Pomegranate 
juice and Pineapple juice inhibit their metabolism. In 
addition, the antidiabetic herbal supplements such as 
bitter melon, fenugreek, cinnamon, Gymnema, ginseng, 
ginger, garlic, Aloe vera, sesame, andrographis paniculata 
and neem potentiate the hypoglycemic activity of 
sulfonylureas pharmacodynamically. The prescribers and 
the pharmacists should be aware of the herbs interacting 
with sulfonylureas to prevent adverse outcomes.
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